In addition, various immunotherapies targeting Aβ in AD model mice were effective in decreasing Aβ deposition in the brains, but it did not lead to improvement of actual symptoms or accumulation of tau (Ostrowitzki et al., 2012; Giacobini and Gold, 2013; Doody et al., 2014; Salloway et al., 2014). Here, MAPT is linked to Alzheimer disease.